KALA
KALA BIO, Inc.
There isn't enough reported data to score KALA yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
KALA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
KALA's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
KALA PE Valuation
KALA has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
KALA Forward outlook
There aren't enough analyst estimates for KALA to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
KALA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$204.63 | +$302.87 |
| Q3 2025 | -$252.50 | +$341.50 |
| Q2 2025 | -$295.50 | +$372.50 |
| Q1 2025 | -$368.00 | +$360.00 |
| Q4 2024 | -$507.50 | +$360.00 |
| Q3 2022 | -$2,862.50 | +$2,237.50 |
| Q2 2022 | -$4,900.00 | +$375.00 |
| Q1 2022 | -$5,375.00 | -$475.00 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 140% for KALA versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
KALA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2022 | $420K | -86% |
| Q2 2022 | $2.1M | -31% |
| Q1 2022 | $1.4M | -58% |
| Q4 2021 | $1.9M | -17% |
| Q3 2021 | $3.1M | +38% |
| Q2 2021 | $3.1M | +266% |
| Q1 2021 | $3.3M | +205% |
| Q4 2020 | $2.2M | +90% |
LLY has the stronger quarterly revenue trend. Revenue is down 100% for KALA versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2022 | -3469% | -2619 points |
| Q2 2022 | -1237% | -285 points |
| Q1 2022 | -2253% | -1386 points |
| Q4 2021 | -2522% | -1227 points |
| Q3 2021 | -850% | +314 points |
| Q2 2021 | -952% | +1603 points |
| Q1 2021 | -867% | +1012 points |
| Q4 2020 | -1295% | +417 points |
KALA's operating margin was −3469% last quarter, down 2619 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
KALA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.5M | +$15M |
| Q1 2026 | -$2.9M | +$5.9M |
| Q4 2025 | -$4.6M | +$42K |
| Q3 2025 | -$10.9M | -$6.2M |
| Q2 2025 | -$16.6M | -$7.3M |
| Q1 2025 | -$8.8M | +$2M |
| Q4 2024 | -$4.6M | +$3.1M |
| Q3 2024 | -$4.7M | -$1.8M |
KALA has burned cash in almost every quarter: −$20M over the past year, against −$35M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over KALA on cash generation, producing positive trailing cash flow while its opponent burns cash.
KALA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -54% | -88.8K shares |
| 1 year | -42% | -52.8K shares |
| 3 years | +145% | +44K shares |
| 5 years | +231% | +51.7K shares |
| Available history | +443% | +60.5K shares |
KALA has the edge over LLY on shareholder dilution, with a more favorable share count trend.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
KALA Net Leverage
KALA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
KALA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 4.7 | Oversold |
KALA's weekly RSI is 33 (neutral) and its Stochastic is 5 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
KALA PE vs Healthcare Sector
KALA has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
KALA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.25 | 36% below |
| 20 week MA | $0.59 | 73% below |
| 50 week MA | $9.99 | 98% below |
| 100 week MA | $160.4 | 100% below |
| 200 week MA | $321.9 | 100% below |
KALA is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over KALA on trend strength, trading above more of its moving averages.
KALA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9,325.0 | $19,150.0 | +105% |
| 2021 | $19,150.0 | $3,400.0 | -82% |
| 2022 | $3,400.0 | $194.0 | -94% |
| 2023 | $194.0 | $350.0 | +80% |
| 2024 | $350.0 | $349.0 | -0.3% |
| 2025 | $349.0 | $32.5 | -91% |
| 2026 YTD | $32.5 | $0.16 | -100% |
KALA's yearly returns have swung widely, from +105% in 2020 to −94% in 2022. It's down 100% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over KALA on returns for 2026, with the stronger performance.